Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: The invention disclosed herein is direct to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in treating neurodegenerative diseases and promoting the generation or survival of neurons in the mammalian brain. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to a method of promoting the generation or survival of neurons in a patient in need thereof in neurodegenerative and related diseases.

Abstract: A load coupling for adjusting torsional natural frequency of a power train includes a first flange having a plurality of annularly arranged connecting holes, a second flange having a plurality of annularly arranged connecting holes and a shaft that extends between the first flange and the second flange. A threaded bore hole is defined within one of the first flange or the second flange radially outward from the plurality of connecting holes. A first threaded plug is seated within the threaded bore hole. The first threaded plug includes a turning end that is axially separated from a contact end. A second threaded plug is seated within the threaded bore hole. The second threaded plug includes a turning end that is axially separated from a contact end. The contact end of the first threaded plug is axially loaded against the contact end of the second threaded plug.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Abstract: A method of projected capacitance touch sensing on a display includes updating the display by applying a drive waveform to each pixel of the display over a plurality of frame periods to update a pixel state. The updating includes selecting each row of the display in turn and repeating a frame update to drive pixels with successive time slices of the drive waveforms. The method further includes sensing a signal from a projected capacitance touch sensing electrode of the display during a sensing interval to provide a touch sensing response; identifying when column drive levels of the drive waveforms for pixels of one selected row change by more than a threshold level between the selected row and a next selected row; and inhibiting the touch sensing responsive to the column drive row change signal indicating a greater than the threshold level change of the drive levels between the selected rows.

Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Abstract: The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPAR? antagonist.

Abstract: A load coupling for adjusting torsional natural frequency of a power train includes a first flange having a plurality of annularly arranged connecting holes, a second flange having a plurality of annularly arranged connecting holes and a shaft that extends between the first flange and the second flange. A threaded bore hole is defined within one of the first flange or the second flange radially outward from the plurality of connecting holes. A first threaded plug is seated within the threaded bore hole. The first threaded plug includes a turning end that is axially separated from a contact end. A second threaded plug is seated within the threaded bore hole. The second threaded plug includes a turning end that is axially separated from a contact end. The contact end of the first threaded plug is axially loaded against the contact end of the second threaded plug.

Abstract: Load couplings, power trains, and methods for adjusting torsional natural frequencies of power trains are provided. In one embodiment, a load coupling includes a first flange, a second flange, and a shaft extending between the first flange and the second flange. The load coupling further includes an annular ring extending radially outward from one of the first flange, the second flange, or the shaft, the annular ring including a plurality of bore holes defined therein, each of the plurality of bore holes including a first opening. The load coupling further includes a first cap connected within one of the plurality of bore holes proximate the first opening, the first cap deformable such that an interference fit is created with the one of the plurality of bore holes.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: A load coupling device for a power train including: a rotatable shaft; a first flange on a first end of the shaft, wherein the first flange is adapted to couple to a first rotating shaft of at a torque producing turbine or a torque driven electrical generator; a second flange on an opposite end of the shaft, wherein the shaft is adapted to couple to a second rotating shaft of the other of the turbine and the generator, and an annular ring extending radially outward from the first flange, wherein the mass of the annular ring is selected to shift a torsional natural frequency of the power train away from an operational condition of the power train. Trim masses may be added to make fine adjustments to the torsional natural frequency of the power train.

Abstract: The invention disclosed herein is direct to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in treating neurodegenerative diseases and promoting the generation or survival of neurons in the mammalian brain. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to a method of promoting the generation or survival of neurons in a patient in need thereof in neurodegenerative and related diseases.

Abstract: Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.

Abstract: Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: A load coupling device for a power train including: a rotatable shaft; a first flange on a first end of the shaft, wherein the first flange is adapted to couple to a first rotating shaft of at a torque producing turbine or a torque driven electrical generator; a second flange on an opposite end of the shaft, wherein the shaft is adapted to couple to a second rotating shaft of the other of the turbine and the generator, and an annular ring extending radially outward from the first flange, wherein the mass of the annular ring is selected to shift a torsional natural frequency of the power train away from an operational condition of the power train. Trim masses may be added to make fine adjustments to the torsional natural frequency of the power train.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.